Bausch + Lomb Corp is gaining traction in the market, with its stock price on the rise.
Today, Bausch + Lomb Corp (BLCO.TO) shares increased by 1.72%, reaching CA$24.77. This uptick follows promising developments in the company's pipeline, especially in advancing treatments for eye health.
Advertisement
Bausch + Lomb Corp
BLCO.TO
BLCO.TO
Bausch + Lomb Corp
WealthAwesomeMarket cap
$8.26B
52W high
$25.70
52W low
$20.25
1W change
-5.34%
Beta
0.56
Analyst Price Targets
Based on analyst covering BLCO · as of Oct 19, 2026
Wall Street analysts forecast BLCO stock price to rise 7.8% over the next 12 months.
Consensus
Moderately BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$25.25
+7.8% Upside
Previously C$25.36 on Oct 16, 2026
Current Price
C$23.42
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on BLCO's historical volatility
30-Day Vol
35.9%
Annualized
90-Day Vol
30.9%
Annualized
Trend (90d)
+19.6%
Annualized drift
90d Mean
C$25.12
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$23.97 | C$21.18 – C$27.14 |
| 60 trading days | C$24.54 | C$20.60 – C$29.24 |
| 90 trading days | C$25.12 | C$20.27 – C$31.14 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Investors might see Bausch + Lomb's recent progress, particularly in treating dry age-related macular degeneration (AMD), as a strong sign of potential future growth.
Bausch + Lomb Corp's Market Cap Reaches CA$8.7 Billion
With a market cap of CA$8.7 billion, Bausch + Lomb is a key player in the eye health sector. However, its financial performance will be crucial for maintaining investor confidence.
Bull case
The company recently announced an oral treatment for dry AMD, BL1243, which has attracted positive attention. With supportive feedback from the FDA, Bausch + Lomb is well-positioned to address a significant unmet need in eye care, potentially leading to increased revenue.
Bear case
Despite the positive developments, Bausch + Lomb's stock faces challenges, including a negative profit margin of -3.21%. Investors should be cautious about the company's ability to become profitable as it continues to invest heavily in research and development.
Advertisement
Recent Developments Fueling Growth
Bausch + Lomb's progress in developing an oral treatment for dry AMD has been a major factor in its stock performance. After a productive meeting with the FDA, the company plans to start its clinical development program in 2027. This could mark a significant step forward in treatment options for patients with limited alternatives.
Market Sentiment and Future Outlook
The positive market response to Bausch + Lomb's advancements shows strong investor sentiment. However, potential investors should weigh the company's current financial challenges, including its negative profit margin. As Bausch + Lomb continues to innovate, its success in turning these advancements into profitable products will be vital for long-term growth.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
